Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7791811 | 0.84 | KDM4E (0.50) | KDM4EGAAATMKMT2AKCNK3 | |
| SCHEMBL7831533 | 0.84 | KCNK3 (0.46) | KDM4EKCNK3KCNK9ALDH1A1HSD17B10 | |
| SCHEMBL12545932 | 0.84 | KDM4E (0.45) | KDM4EGAAATMKMT2AKCNK3 | |
| SCHEMBL254882 | 0.83 | TSHR (0.59) | KDM4EGAAATMKMT2AKCNK3 | |
| SCHEMBL3511611 | 0.83 | TSHR (0.57) | KDM4EGAAATMKMT2ALMNA | |
| SCHEMBL29277714 | 0.83 | KDM4E (0.46) | KDM4EKMT2AKCNK3KCNK9LMNA | |
| Hydrogen Peroxide SCHEMBL28473316 | 0.82 | TSHR (0.57) | KDM4EGAAATMKMT2AKCNK3 | |
| SCHEMBL647215 | 0.81 | CA1 (0.55) | KDM4EGAAATMKMT2AKCNK3 | |
| SCHEMBL18763821 | 0.81 | KDM4E (0.50) | KDM4EGAAATMKMT2AKCNK3 | |
| SCHEMBL16957768 | 0.80 | GABRA1 (0.43) | KMT2AKCNK3KCNK9LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020163673-A1 | INHIBITORS OF ADENYLATE-FORMING ENZYME MENE | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-08-13 | — | — | WO | disclosed |
| US-7662821-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | BAYER SCHERING PHARMA AG (DE) | 2010-02-16 | — | — | US | disclosed |
| US-7659297-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | Bayer Schering Pharma, AG (DE) | 2010-02-09 | — | — | US | disclosed |
| CN-100581543-C | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG | 2010-01-20 | — | — | CN | disclosed |
| US-7638515-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-29 | — | — | US | disclosed |
| CN-1889947-A | Tetrahydronaphthalene derivatives, process for their preparation and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-01-03 | — | — | CN | disclosed |
| EP-1670458-B1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| EP-1670458-A1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-21 | — | — | EP | disclosed |
| US-20050272823-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-08 | — | — | US | disclosed |
| US-20050209324-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-09-22 | — | — | US | disclosed |
| US-20050171109-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-04 | — | — | US | disclosed |
| WO-2005034939-A1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171109-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | TNF, DHPS, PTGES | KDM4E 3610/4885GAA 3039/4885ATM 4333/4885 |
| US-20050272823-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | DHPS, TNF, PTGES | KDM4E 3612/4885GAA 3349/4885ATM 4346/4885 |
| US-20050209324-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | TNF, DHPS, PTGES | KDM4E 3610/4885GAA 3039/4885ATM 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.